Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04949191
Title The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation

Advanced Solid Tumor



Pembrolizumab + Pemigatinib

Pemigatinib + Retifanlimab

Age Groups: adult | senior
Covered Countries USA | ITA

No variant requirements are available.